Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
CALL
United States Natural Gas Fund
UNG
$496M
| $34M | 0.01% |
447,775
-129,975
| -22% | -$13.4M |
|
1302
PUT
KKR & Co
KKR
$103B
| $34M | 0.01% |
734,300
+246,400
| +51% | +$12.9M |
|
1303
PUT
Bilibili
BILI
$7.26B
| $33.9M | 0.01% |
1,326,000
-1,268,200
| -49% | -$30.5M |
|
1304
CALL
AstraZeneca
AZN
$241B
| $33.9M | 0.01% |
256,654
-138,300
| -35% | -$18.1M |
|
1305
CALL
Cencora
COR
$59.1B
| $33.9M | 0.01% |
239,600
+59,500
| +33% | +$9.1M |
|
1306
PUT
Teva Pharmaceuticals
TEVA
$42.5B
| $33.9M | 0.01% |
4,507,900
+1,315,400
| +41% | +$11.5M |
|
1307
Xylem
XYL
$27.9B
| $33.9M | 0.01% |
433,161
+300,433
| +226% | +$24.8M |
|
1308
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$67.7B
| $33.8M | 0.01% |
422,871
+412,029
| +3,800% | +$33.6M |
|
1309
PUT
PENN Entertainment
PENN
$2.55B
| $33.8M | 0.01% |
1,111,684
-234,562
| -17% | -$7.92M |
|
1310
PUT
Aramark
ARMK
$16.4B
| $33.7M | 0.01% |
1,525,578
+1,349,406
| +766% | +$33.3M |
|
|
SIVB
1311
PUT
DELISTED
SVB Financial Group
SIVB
| $33.7M | 0.01% |
85,400
-75,400
| -47% | -$35.5M |
|
1312
Allstate
ALL
$65.7B
| $33.7M | 0.01% |
266,063
-465,493
| -64% | -$61M |
|
1313
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.58B
| $33.7M | 0.01% |
986,554
+510,537
| +107% | +$15.9M |
|
|
IMGO
1314
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $33.7M | 0.01% |
2,517,041
+18,620
| +0.7% | +$296K |
|
1315
CALL
XPO
XPO
$25B
| $33.7M | 0.01% |
1,176,754
+433,541
| +58% | +$13.8M |
|
1316
PUT
Monster Beverage
MNST
$91.7B
| $33.6M | 0.01% |
1,452,000
+973,200
| +203% | +$21.2M |
|
1317
CALL
Celsius Holdings
CELH
$7.29B
| $33.6M | 0.01% |
1,546,500
+440,400
| +40% | +$8.49M |
|
1318
CALL
Kohl's
KSS
$2.23B
| $33.6M | 0.01% |
942,400
-493,200
| -34% | -$24.2M |
|
1319
PUT
Intercontinental Exchange
ICE
$86.5B
| $33.6M | 0.01% |
357,500
+252,700
| +241% | +$27M |
|
|
XIFR
1320
XPLR Infrastructure LP
XIFR
$1.1B
| $33.5M | 0.01% |
452,305
+144,168
| +47% | +$10.3M |
|
1321
Kinross Gold
KGC
$32.6B
| $33.5M | 0.01% |
9,368,607
+7,642,542
| +443% | +$37M |
|
1322
IPG Photonics
IPGP
$3.61B
| $33.5M | 0.01% |
356,176
+291,436
| +450% | +$28.8M |
|
1323
Nike
NKE
$60.7B
| $33.5M | 0.01% |
327,714
-138,992
| -30% | -$16.4M |
|
1324
UDR
UDR
$12.2B
| $33.4M | 0.01% |
726,009
+685,797
| +1,705% | +$34.6M |
|
1325
C.H. Robinson
CHRW
$17.5B
| $33.4M | 0.01% |
329,713
-1,179,321
| -78% | -$123M |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.